جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.
AA

Anas A Abdulkader

بانتظار توثيق الانتساب2024–2026
9وثائق Scopus
25استشهاداً
3مؤشر h
0منها بانتماء الجامعة
إجمالي Scopus (كل الجهات)
مقالوصول مغلق2026

Trends in Cardiomyopathy and Atrial Fibrillation-Related Mortality Among US Adults, 1999–2024

Population Health Management · مجلد 29 (4) · 233-241

Atrial fibrillation (AF) is a highly prevalent comorbidity in patients with cardiomyopathy (CM), associated with worse cardiovascular outcomes. This study aims to provide a comprehensive, national-level analysis of AF and CM-related mortality in the United States. The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was utilized, using death certificates from 1999 to 2024. The study included patients aged ≥15 years with CM and AF. Statistical analyses were conducted to calculate age-adjusted mortality rates (AAMRs) per 100,000 individuals and annual percent changes with 95% confidence intervals (CIs). Between 1999 and 2024, CM with concomitant AF accounted for 134,470 deaths among individuals aged 15 years or older. The overall AAMR rose from 1.5 per 100,000 in 1999 to 2.3 in 2024. From 1999 to 2016, the AAMR rose modestly (1.5-1.8), followed by a pronounced rise from 2016 to 2022 (1.8-2.5), and a relative decline by 2024 (2.5-2.3). Compared with 2019, mortality in 2020 demonstrated a 15% relative increase (incidence rate ratio = 1.15; 95% CI: 1.11-1.19). Males had disproportionately higher AAMRs compared to females. By race, the highest AAMRs were observed in non-Hispanic (NH) Black and White populations (1.8 each). Regionally, the West and Midwest exhibited the highest AAMRs (1.9 each). Urban-rural stratification revealed higher AAMRs among rural areas (2.2) when compared with urban (1.8) areas. Targeted public-health interventions and resource allocation to address this growing cardiovascular mortality burden, particularly in high-risk demographic groups, are needed.

cardiomyopathyatrial fibrillationmortality trendscomorbidities
مقالوصول مفتوح2026

Elevated symptoms of muscle dysmorphia and disordered eating among male gym-goers in Riyadh: a cross-sectional screening study

Journal of Eating Disorders · مجلد 14 (1)

BACKGROUND: Muscle dysmorphia (MD) refers to distressing concerns about being insufficiently muscular and is increasingly reported among gym-going men. Evidence from Saudi Arabia is limited. This study estimated the proportion of gym-going men in Riyadh who screened positive for elevated MD symptomatology and examined associations with disordered eating symptoms and sociodemographic factors. METHODS: A cross-sectional survey was conducted among male gym-goers in Riyadh. Elevated MD symptomatology was assessed using the Muscle Dysmorphic Disorder Inventory (MDDI), and disordered eating symptoms were screened using the Patient Health Questionnaire-Eating Disorders Module (PHQ-ED). Group differences were examined using appropriate bivariate tests. A stepwise binary logistic regression model was used to identify predictors of screening-positive status for elevated MD symptomatology (MDDI ≥ 39). RESULTS: Of 303 participants, 49.8% screened positive for elevated MD symptomatology (MDDI ≥ 39). Screening-positive PHQ-ED status was associated with screening-positive MDDI status (Fisher's exact test, p = 0.030). In the final stepwise multivariable model, marital status and graduate-level education were associated with screening-positive MDDI status. Body mass index (BMI) was not retained in the final stepwise model, and PHQ-ED status could not be evaluated in the multivariable model due to sparse data/complete separation (non-estimable odds ratios). CONCLUSIONS: Nearly half of the surveyed gym-going men screened positive for elevated MD symptomatology, indicating a high symptom burden in this selected sample. These findings should not be interpreted as diagnostic prevalence. Screening-based approaches in gym settings may help identify individuals who report high distress or interference and may benefit from further clinical assessment. Larger studies using probability sampling and structured diagnostic interviews are needed to estimate diagnostic prevalence and clarify associated factors.

muscle dysmorphiadisordered eatinggym membersscreening
مراجعةوصول مفتوح202513استشهاد· Semantic Scholar

Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia; a network meta-analysis of randomized controlled trials

Lipids in Health and Disease · مجلد 24 (1) · 109-109

BACKGROUND: Hypertriglyceridemia is an independent risk factor for cardiovascular diseases. In previous trials, apolipoprotein C-III (APOC3) inhibition through the antisense oligonucleotides volanesorsen, olezarsen, and plozasiran reduced triglyceride levels. However, the three medications' safety and efficacy have yet to be compared. METHODS: A network meta-analysis was performed to compare multiple doses of the three medications to each other through the placebo. Randomized controlled trials (RCTs) were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane until November 22nd, 2024. The mean difference (MD) and 95% confidence interval (CI) were used for continuous outcomes. The risk ratio (RR) and 95% CI were used for dichotomous outcomes. RESULTS: Ten RCTs with a total of 1,129 patients were included. volanesorsen 300 mg once weekly showed the most significant percent reduction in triglyceride levels (MD = -91.0%, 95% CI: (-109.2%; -72.8%); P < 0.01). Only plozasiran once monthly, regardless of the dose, showed a non-significant percent reduction in triglycerides. This finding should be taken cautiously as the data were derived from a phase 1 trial with a small sample size. All the regimens significantly reduced APOC3 levels compared to placebo, with plozasiran 100 mg monthly and volanesorsen 300 mg once weekly showing the most significant reduction (MD range: -92.8% to -88.5%; P < 0.01). None of the treatments showed a statistically significant difference in overall adverse events rate compared to the placebo. CONCLUSION: APOC3 antisense oligonucleotide inhibitors effectively reduced triglyceride and APOC3 levels in hypertriglyceridemia with an acceptable safety profile. However, the results should be interpreted cautiously due to the small sample size. Further research is needed to confirm the beneficial effects of APOC3 inhibitors and show strong evidence of the impact of each regimen.

hypertriglyceridemiaantisense oligonucleotidesapolipoprotein C-IIIvolanesorsen
مراجعةوصول مفتوح20256استشهاد· Semantic Scholar

Integrating malaria vaccine and CRISPR/Cas9 gene drive: a comprehensive strategy for accelerated malaria eradication

Malaria Journal · مجلد 24 (1) · 17-17

Malaria remains a significant public health challenge, particularly in low- and middle-income countries, despite ongoing efforts to eradicate the disease. Recent advancements, including the rollout of malaria vaccines, such as RTS,S/AS01 and R21/Matrix-M™, offer new avenues for prevention. However, the rise of resistance to anti-malarial medications necessitates innovative strategies. This review explores the potential integration of CRISPR/Cas9 gene drive technology with malaria vaccination efforts to enhance vector control and reduce transmission. By employing gene drive mechanisms for population suppression and replacement of malaria-transmitting Anopheles mosquitoes, combined with the immunogenic properties of vaccines, a synergistic approach can be established. This paper discussed the need for integrated strategies to address the biological complexities of malaria and socio-economic factors influencing its prevalence. Challenges such as regulatory hurdles, community acceptance, ecological impacts, and sustainable funding are examined, alongside strategies for implementation within existing malaria control programmes. This integrated approach could significantly contribute to achieving the World Health Organization's targets for malaria reduction by 2030, ultimately enhancing public health outcomes and supporting broader socio-economic development.

malaria eradicationCRISPR-Cas9 gene drivemalaria vaccineRTS,S/AS01
مراجعةوصول مغلق20251استشهاد· Semantic Scholar

Angiotensin-neprilysin inhibition in acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials

European Heart Journal · مجلد 46 (Supplement_1)

Abstract Purpose Angiotensin receptor-neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety when initiated in acute decompensation (ADHF) remain less well characterized. This meta-analysis evaluates the efficacy and safety of ARNI compared to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for ADHF. Methods A meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, Scopus, WOS, Embase, and CENTRAL till November 2024. Risk ratios (RR) were applied for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI). Results Three RCTs with 1,741 patients were included. Use of ARNI after stabilization of ADHF resulted in a significant reduction of HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57 to 0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57 to 0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64 to 1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; p < 0.0001) or 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; p = 0.0001). However, ARNI was associated with a higher risk of symptomatic hypotension (RR: 1.33; 95% CI: 1.04 to 1.71; p = 0.024). Conclusion Pooled data demonstrate that the initiation of ARNI post-ADHF can be effective compared with ACEIs/ARBs for both cardiovascular and renal benefits at the expense of increased risk for symptomatic hypotension.

angiotensin receptor-neprilysin inhibitorsacute decompensated heart failureACE inhibitorsangiotensin receptor blockers
مراجعةوصول مفتوح20251استشهاد· Semantic Scholar

Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions

Annals of Medicine and Surgery · مجلد 88 (3) · 2298-2311

Chronic limb-threatening ischemia (CLTI) represents the most severe form of peripheral artery disease (PAD), driven by both advanced atherosclerosis and chronic inflammation. Despite advancements in revascularization and medical therapy, outcomes remain poor. Inflammation has emerged as a key therapeutic target, and several anti-inflammatory agents are under investigation for potential benefit in CLTI. A comprehensive literature review was conducted using PubMed, Scopus, Embase, Google Scholar, and Web of Science to identify studies published between 1990 and 2025. Keywords included "chronic limb-threatening ischemia," "peripheral artery disease," "colchicine," "canakinumab," "methotrexate," "NLRP3 inflammasome," and "anti-inflammatory therapy." Eligible studies included original research, clinical trials, systematic reviews, and relevant guidelines focused on inflammation-targeted interventions in atherosclerosis and limb ischemia. Colchicine has shown significant reductions in major adverse cardiovascular events in large trials and retrospective PAD studies, though no randomized controlled trials (RCTs) have specifically addressed CLTI. Canakinumab reduced inflammatory biomarkers and improved walking performance in PAD but had no effect on plaque progression. Methotrexate did not demonstrate cardiovascular benefit in the Cardiovascular Inflammation Reduction Trial. Preclinical agents targeting the NLRP3 inflammasome (e.g., MCC950) have shown anti-inflammatory effects but lack human data. Nutraceuticals, including omega-3 fatty acids and polyphenols, may offer adjunctive benefits, though evidence remains limited. Inflammation-modulating therapies hold promise as adjuncts in CLTI management, potentially improving outcomes by targeting the underlying immune mechanisms of disease progression. However, current evidence is insufficient for clinical adoption in CLTI. Large-scale, well-designed RCTs focusing on limb-specific outcomes are necessary to clarify the role of these therapies in high-risk vascular populations.

critical limb ischemiaperipheral arterial diseaseinflammationanti-inflammatory therapy
مراجعةمفتوح (مستودع)2025

Angiotensin-neprilysin inhibition in acute decompensated heart failure: a meta-analysis of randomized controlled trials

Future Cardiology · مجلد 22 (1) · 43-55

Background Angiotensin receptor – neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety after stabilization of acute decompensation (ADHF) remain unclear. This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.Methods Meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024. Risk ratios (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) were used.Results Three RCTs (1,741 patients) were included. ARNI use after ADHF stabilization significantly reduced HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57–0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57–0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64–1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: −0.24; 95% CI: −0.34 to −0.14; p < 0.0001) and 8 weeks (SMD: −0.21; 95% CI: −0.31 to −0.10; p = 0.0001). However, ARNI increased symptomatic hypotension risk (RR: 1.33; 95% CI: 1.04–1.71; p = 0.024).Conclusion initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.Protocol registration PROSPERO: CRD42024618027.

angiotensin receptor-neprilysin inhibitorsacute decompensated heart failureACE inhibitorsangiotensin receptor blockers
مقالوصول مفتوح20244استشهاد· Semantic Scholar

Olfactory Neuroblastoma Causing Cushing’s Syndrome Due to the Ectopic Adrenocorticotropic Hormone (ACTH) Secretion: A Case Report

Cureus · مجلد 16 (3) · e56434-e56434

Cushing's syndrome is a constellation of features occurring due to high blood cortisol levels. We report a case of a 47-year-old male with a history of recurrent olfactory neuroblastoma (ONB). He presented with bilateral lower limb weakness and anosmia and was found to have Cushing's syndrome due to high adrenocorticotropic hormone (ACTH) levels from an ectopic source, ONB in this case. Serum cortisol and ACTH levels declined after tumor removal.

olfactory neuroblastomaCushing's syndromeectopic ACTH syndromeACTH
مراجعةوصول مغلق2024

Abstract 4139723: Safety and Efficacy of Antisense Oligonucleotides On Triglyceride and Apolipoprotein C-III Levels in Hypertriglyceridemia; A Network Meta-Analysis Of Randomized Controlled Trials

Circulation · مجلد 150 (Suppl_1)

Background: Hypertriglyceridemia is an independent risk factor for cardiovascular diseases. Apolipoprotein C-III (APOC3) inhibition through the antisense oligonucleotides volanesorsen, olezarsen, and plozasiran, reduced triglycerides in the previous trials. However, the safety and efficacy of the three medications have not been compared yet. Methods: A network meta-analysis was performed to compare multiple doses of the three medications to each other through the placebo. Nine randomized controlled trials (RCTs) were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane. The mean difference (MD) and 95% confidence interval (CI) were used for continuous outcomes. The risk ratio (RR) and 95% CI were used for dichotomous outcomes. Results: A total of 782 patients were included. Volanesorsen 300 mg once weekly showed the most significant reduction in triglyceride levels (MD = -90.98%, 95% CI: [-109.2%; -72.8%]; p<0.01 ). Only plozasiran once monthly, regardless of the dose, showed a non-significant reduction in triglycerides, which should be taken with caution as the data were derived from a phase 1 trial with a small sample size. All the regimens significantly reduced APOC3 levels compared to placebo with plozasiran 100 mg and 50 mg once monthly and volanesorsen 300 mg once weekly, showing the most significant reduction (MD range: -92.8% to -88.4%; p<0.01 ). Plozasiran regimens, especially the 25 mg, 50 mg, and 10 mg once monthly dosages, respectively, reduced total cholesterol levels the most compared to placebo (MD range: -30.6% to -23.5%; p<0.01 ). Only volanesorsen, regardless of the dose, did not significantly reduce total cholesterol compared to placebo. None of the treatments showed a statistically significant difference in the adverse events rate compared to placebo. Conclusion: APOC3 antisense oligonucleotide inhibitors effectively reduced triglyceride, APOC3, and total cholesterol levels in hypertriglyceridemia, with an acceptable safety profile. However, due to the relatively small sample size, the results should be interpreted with caution. Further research is needed to confirm the beneficial effects of APOC3 inhibitors and provide strong evidence on the effects of each medication regimen.

hypertriglyceridemiaantisense oligonucleotidesapolipoprotein C-IIIvolanesorsen